Skip to main
  1. Stocks
  2. PaySign Inc
  3. Forecast
PAYS

PaySign Inc (PAYS) Stock Forecast & Price Target

PaySign Inc (PAYS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PaySign is favored because its Pharmaceutical Patient Affordability segment is scaling rapidly, with 2Q revenue up 89% Y/Y to $14.6M, 148 active programs, and management expecting roughly 50-55 net new programs per year, supporting a longer runway for growth. The company’s dynamic business rules and 97% claim accuracy appear to be a real competitive moat, helping clients save more than $325M in 2025 while driving share gains from smaller competitors and lifting average revenue per program to $324K in 2025. Financially, the business is strengthening as 2Q adjusted free cash flow reached $6.8M, adjusted EBITDA rose 113% Y/Y to $9.6M, margins expanded to 34.0%, and the company ended with $27.4M in unrestricted cash, $149.1M in restricted cash, and no debt.

Bears say

PaySign is still fundamentally exposed to a narrow and volatile revenue base, as the domestic Plasma Donor Compensation niche generated just over 55% of revenue in 2025, leaving the business vulnerable to shifts in donation volumes, regulation, or consolidation among plasma center operators. The company’s 2020 results show how quickly that concentration can damage performance, with revenue falling 30% year over year to $24M and adjusted EBITDA swinging from a positive $10.1M in 2019 to a $2.8M loss, underscoring limited resilience when end markets weaken. Competitive pressure, reliance on a small number of bank partners, and heavy compliance and data-security obligations further threaten margins and market share, while 25% insider ownership and a low float can limit shareholder influence and increase volatility.

PaySign Inc (PAYS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.

PaySign Inc (PAYS) Analyst Forecast & Price Prediction

Get the latest PaySign Inc (PAYS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PaySign Inc (PAYS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PaySign Inc (PAYS) Forecast

Analysts have given PaySign Inc (PAYS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, PaySign Inc (PAYS) has a Strong Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PaySign Inc (PAYS)


PaySign Inc (PAYS) Analyst Forecast & Price Prediction

Get the latest PaySign Inc (PAYS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PaySign Inc (PAYS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PAYS stock data and trends